Latest Breaking News On - Critical care medicine - Page 8 : comparemela.com

Brainomix Achieves Breakthrough with FDA Clearance of e-Lung AI Software

·        Established market leader in stroke AI imaging receives its first FDA clearance in the lung imaging space.·        With this expanded foundation of AI-driven healthcare solutions, the Oxford-based company remains committed t.

United statesUniversity of chicagoSan diegoUnited kingdomDeji adegunsoyeAvalyn pharmaMichalis papadakisHeidelberg universityAmerican thoracic societyAssistant professorScientific directorInterstitial lung disease programChicago medicineAmerican journalCritical care medicineIdiopathic pulmonary fibrosis

Ex-cigarette smokers who vape may be at higher risk for lung cancer

Former cigarette smokers who use e-cigarettes or vaping devices may be at higher risk for lung cancer than those who don t vape, according to research published at the ATS 2024 International Conference.

South koreaUnited statesKyonggi doRepublic of koreaYeon wook kimAmerican cancer societyDepartment of internal medicineDivision of pulmonaryInternational conferenceSeoul national university bundang hospitalUs preventive services task forceRepublic of korea national health screening programCritical care medicineInternal medicineNational health screening programServices task force

Hospital diversity linked to higher mortality rates for ventilated patients

The odds of death for patients receiving mechanical ventilation for pneumonia or sepsis increase along with the diversity of hospitals' patient populations, suggesting more systemic factors such as lack of resources and income levels may be to blame, according to research published at the ATS 2024 International Conference.

United statesAmerican thoracic societyDivision of pulmonary sciencesInternational conferenceUniversity of colorado anschutz medical campusPulmonary sciencesCritical care medicineColorado anschutz medicalHealthcare costUtilization projectState inpatient databases

Dupixent® (dupilumab) Late-Breaking Data from NOTUS Confirmatory Phase 3 COPD Trial Presented at ATS and Published in The New England Journal of Medicine

NOTUS results confirm landmark data from the Phase 3 BOREAS trial and show Dupixent significantly reduced exacerbations by 34% and improved lung function, compared to placebo, in uncontrolled chronic.

United statesFrance generalArnaud delepineSurya bhattTimothy gilbertTarik elgoutniCorentine driancourtNathalie phamRegeneron velocimmuneEvan berlandHanna hodgeVesna tosicThomas kudsk larsenGeorged yancopoulosFelix lauscherAmerican thoracic society

Press Release: Dupixent® late-breaking data from NOTUS confirmatory phase 3 COPD study presented at ATS and published in NEJM

Press Release: Dupixent® late-breaking data from NOTUS confirmatory phase 3 COPD study presented at ATS and published in NEJM
marketscreener.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from marketscreener.com Daily Mail and Mail on Sunday newspapers.

United statesFrance generalTimothy gilbertSurya bhattCorentine driancourtTarik elgoutniNathalie phamEvan berlandThomas kudsk larsenHanna hodgeVesna tosicFelix lauscherExchange commissionUniversity of alabama at birminghamRegeneron genetics centerUs department of justice